

Curriculum Vitae and Bibliography

Name: Eric Charles Holland
Date of Birth: 2/7/59
Place of Birth: New Orleans, LA
Nationality: USA

Office Address: Division of Human Biology
Fred Hutchinson Cancer Research Center
C3-103
1100 Fairview Dr. N.
Seattle, WA
Tel: 206-667-6117
Email: ehollande@fhcrc.org

Education: Miami University, Oxford OH
1977-1981, **BS** - Chemistry,
University of Chicago, Chicago IL
1981-1985, **PhD** - Biochemistry and Molecular Biology
Stanford University, Stanford CA
1985-1990, **MD**

Postdoctoral Training:

1990-1991	Internship in Surgery, UCLA
1992-1995	Residency in Neurosurgery, UCLA
1986-1988	Post-Doc, HIV gene expression, Stanford University - Paul Berg's laboratory
1995-1998	Post-Doc, Transgenic models for glioma, NIH - Harold Varmus' laboratory

Board Certified in Neurological Surgery

Positions and Appointments

1998-2000

MD Anderson Cancer Center

Primary Appointment:
Assistant Professor
Department of Neurosurgery
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Joint Appointment:
Assistant Professor
Department of Molecular Genetics
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Memorial Sloan Kettering Cancer Center New York, N.Y.

Cornell University New York, N.Y.

2000 – 2006

Associate Attending/Member

Associate Professor

2006-2013

Primary Appointment
Attending Surgeon

Affiliate Appointment
Professor

Department of Neurosurgery
Memorial Hospital for Cancer and Allied
Diseases, New York, N.Y.

Joint Appointment

Department of Surgery

Vice Chairman for Translational Research

Memorial Hospital for Cancer and Allied
Diseases, New York, N.Y.

Joint Appointment

Department of Neurology

Memorial Hospital for Cancer and Allied
Diseases, New York, N.Y.

Joint Appointment

Member

Cancer Biology and Genetics Program

Sloan Kettering Institute for Cancer

Research, New York, NY

Program in Cell Biology and Genetics

Department of Neurosurgery

Cornell University, New York, N.Y.

Affiliate Appointment

Department of Neurosurgery

Cornell University, New York, N.Y.

Director of the Brain Tumor Center at MSKCC

Emily Tow Jackson Chair in Oncology at MSKCC

2013-Present

Senior Vice President

Director, Human Biology Division

Fred Hutchinson Cancer Research Center, Seattle, WA

Director, Solid Tumor Translational Research (STTR)

Fred Hutchinson Cancer Research Center, Seattle, WA

University of Washington, Seattle, WA

Professor, Department of Neurological Surgery

University of Washington, Seattle, WA

Director, Nancy and Buster Alvord Brain Tumor Center

Chap and Eve Alvord and Elias Alvord Chair in Neuro-Oncology

University of Washington, Seattle, WA

Member, Institute of Medicine

Honors and Awards

2014 – Honorary Doctorate, Uppsala University

2010 - Altman Award

2009 – Voynick Award

2004 – Farber Award

2002 - Seroussi Award

2001 – Bressler Scholars Award

2000 - American Brain Tumor Association Research Award

2000 - Peter A. Steck Memorial Award

2000 – 2003 - Searle Scholars Award

1995 – 1998 - Howard Hughes Medical Institute Post Doctoral Fellow

Named Lectureships:

Hans-Dietrich Hermann Lecture for Brain Oncology, Hamburg, Germany, February 2012
 Sandie Altman Lecture, U Penn, Philadelphia, PA, June 2010
 Voynick Lecture, Yale, New Haven, CN, January 2009
 Bittner Lecture, AANS, Chicago, IL, April 2008
 Killan Lecture, Montreal Neurologic Institute, Montreal, Canada, March 2005
 Pudenz Lecture, Amer. Soc. Ped. Neurosurg, Maui, HI, February 2005
 Farber Lecture, Society for Neuro-oncology, Toronto, Canada, November 2004.
 Lebatt Lecture, University of Toronto, Toronto, Canada, January 2004
 Hoshino Lecture, UCSF, San Francisco, CA, September 2003

NIH GRANTS**Completed**

2002 - 2004 PI, Brain tumor SPORE program, P20 CA97011
 2001 – 2004 PI, RO1 CA94842
 1999 – 2004 Co-PI, UO1 CA894314-1 (MMHCC)
 2002 - 2005 Co-PI, RO1 CA/NS96582-01 (Marilyn Resh, PI)
 2003 - 2008 PI, RO1 CA099489
 2004 – 2009 Co-PI, RO1 CA102673 (Ron Blasberg, PI)
 2004 – 2009 Co-PI, UO1 CA04002 (Pier Paolo Pandolfi PI, MMHCC)
 2006 – 2011 PI, U54 CA126518-01 (TMEN)
 2012 - 2013 PI, T32CA157323-01A1

Active

2003 – 2014 PI, RO1 CA100688
 2009 – 2014 PI, UO1 CA141502-01 (MMHCC)
 2009 – 2014 Co-PI U54 CA143798 (Franziska Michor, PI, PS-OC)
 2011 – 2016 PI, U54CA163167-01 (TMEN)
 2013 – 2018 Co-PI U01CA105492 (Dolores Hambarzumyan, PI)

COMMITTEE MEMBERSHIPS:**National and International**

1999 - present National Cancer Institute Mouse Model for Human Cancer Consortium
 Steering Committee Member (MMHCC).
 2000 Co-chair of animal models committee of the Brain Tumor Process
 Review Group meeting (NCI)
 2002 Chair, Preclinical trials subcommittee, MMHCC
 2006-present National Cancer Institute Tumor Microenvironment Network Steering
 committee Member (TMEN)

INTERNATIONAL MEETINGS ORGANIZED

2000 NCI Preclinical trials Rockville MD
 2002 Workshop: Preclinical trials Jackson Labs, Bar Harbor, ME
 2002 Symposium: Preclinical trials Jackson Labs, Bar Harbor, ME

NIH PEER REVIEW

2002 PO1 site visit – St Jude Children’s Hospital
 2002 Ad Hoc reviewer, Path C Study section
 2002 PO1 site visit, U. Mass medical school
 2002-2003 Ad Hoc reviewer, Subcommittee C
 2002-2003 Member, CAMP Study Section

2003- Member, Cancer Genetics Study Section
2005 Ad Hoc PO1 NF1 cluster review

SCIENTIFIC SOCIETIES

Society for Neuro-Oncology
American Association of Neurologic Surgeons
Congress of Neurological Surgeons
American Association for Cancer Research
Society for Neuroscience

ACADEMIC CONSULTANTSHIPS:

1. Ad Hoc reviewer, Dana Farber Harvard Cancer Center External Advisory Board 2007
2. Consultant to Steven Rosenfeld MD, University of Alabama, Birmingham for Brain Tumor SPORE program development. 2002
3. Consultant to Jeffery Bruce MD, Columbia University, for Brain Tumor SPORE program development. 2002
4. Consultant to Cliff Schold MD, UPMC Health System, Pittsburgh, PA for Brain Tumor SPORE program development, July 2001
5. Consultant to Ian Pollock, MD, UPMC Health System, Pittsburgh, PA, for Program Project Grant entitled "Novel strategies for brain tumor therapy", January 2000.
6. Consultant to Michael T. Lotze, MD, UPMC Health System, Pittsburgh, PA, for Program Project Grant entitled "Cytokine gene therapy of Cancer", June 1999.

EDITORIAL BOARDS

1. Neoplasia
2. Virology
3. Molecular Medicine
4. Molecular Cancer Research
5. International Journal of Cancer
6. Neuro-Oncology
7. Glia

FORMAL TEACHING:

Courses taught:

1. Lecturer, GSK graduate school, MSKCC 2006-2011
2. Lecturer, UAB Graduate Course in gliomas Birmingham Al, March 2004
3. Lecturer, topic Neurosurgical evaluation of patients, Cornell University Medical School 2002-2005
4. Lecturer, Topic: Brain development and brain tumor formation, in Cell Biology course. Cornell University Graduate School. May 2002
5. Lecturer, Topic: Oncogenes and tumor suppressors, In: Molecular Genetics course. Cornell University Graduate School. November, 2001, 2002, 2004, 2005
6. Invited Speaker: Somatic cell gene transfer modeling of gliomas. Pancreatic Cancer Working Group, The University of Texas M. D. Anderson Cancer Center, Houston, TX, August 2000.
7. Lecturer, Topic Retroviruses II. Eukariotic gene expression course, University of Texas Houston Health Science Center GSBS, Houston, TX, April 2000.
8. Lecturer, Topic Retroviruses I. Eukariotic gene expression course, University of Texas Houston Health Science Center GSBS, Houston, TX, April 2000.

9. Chair, Advances in Oncology Institutional Grand Rounds, Modeling Cancer in Mice: The molecular and cellular origins of human gliomas. Lecture entitled Modeling gliomas in mice with RCAS/tv-a. April 2000
10. Lecturer, Genetics of Brain Tumors. Department of Neurosurgery Didactic Lecture Series, UTMDACC, Houston, TX, January 1999.
11. Seminar, Somatic cell gene transfer to model gliomas in mice. Information Exchange Seminar series, Department of Molecular Genetics, UTMDACC, Houston, TX, April, 1999.
12. Lecturer, Retroviruses II. University of Texas Houston Health Science Center GSBS, Houston, TX, April 1999.
13. Lecturer, Retroviruses I. University of Texas Houston Health Science Center GSBS, Houston, TX, April 1999.

SUPERVISORY TEACHING:

Graduate students directly supervised:

1999 – 2003	Chengkai Dai, PhD, U. Texas (now @ Jackson Labs)
1999 – 2003	Meena Tanwar, PhD, Student, U. Texas (Pediatrics @ Tucson)
2000 – 2004	Xiaoyi Hu, PhD, student, Cornell U (HemeOnc fellow @ Wash. U)
2001 – 2005	Alan Shih, MD, PhD, student, Cornell, (oncology fellow @ MSK)
2004 – 2010	Elena Fomchencko, PhD student, Cornell University (Neurosurgery @ Yale)
2005 – 2010	Nikki Charles, PhD, student, Cornell University (post-doc @ MSK)
2006 – 2011	Amanda Katz, PhD, student, Cornell University (Champ. of Oncology)
2007 – 2008	Daniel Halperin, HHMI medical student Cornell University (Fellow @ BWH)
2008 – 2013	Bo Wee, PhD student, Cornell University (?)
2009 – 2013	John Halliday, PhD student, GSK (Investment banking)
2009 - 2011	Karim Helmy, MD, PhD student, RWJMS (Fellow @ BWH)
2009 – 2013	Ken Pitter, MD, PhD student, Cornell University
2010 – 2011	Moritz Orstat, MD, PhD student, University of Essen, Germany
2010 – 2012	Yu-Kang Chang, PhD student, Cornell University (now @ Dana Farber)

Doctoral Thesis Opponent/External Reviewer

2003	Goran Hessler, MD, PhD, Uppsala University, Sweden
2004	Stephanie Backman, PhD, University of Toronto, Canada
2005	Marcela Assanah, PhD, Columbia University
2006	Clair Fraizer, PhD, Rockefeller University
2011	Richard Able, PhD, CCNY

Postgraduates directly supervised:

1999	Daniel Fults, MD, Professor of Neurosurgery, U. of Utah (sabbatical)
2000 – 2003	V. K. Rajasekhar PhD, visiting scientist (now @ MSKCC)
2001 – 2003	Lene Uhrbom PhD, Postdoctoral Fellow, (now @ Uppsala University, Sweden)
2001 – 2003	Martin Begemann, MD Neurology Fellow (now @ Mt Sinai)
2002 – 2005	Andrew Lassman, MD (now @ Columbia University)
2004 – 2005	Pierre Francois Carton, PhD, post-doc (now @ INSERM Nantes, France)
2004 – 2007	Hiroyuki Momota, MD, PhD Neurosurgery Fellow/post doc (now @ National Cancer Center, Tokyo Japan)
2004 – 2010	Oren Becher, MD Pediatric Oncology Fellow (now @ Duke University)
2005 - 2009	Fabienne Bernet, PhD, Postdoctoral Fellow (now @ Cornell University)
2005 – 2010	Dolores Hambarzumyan, PhD, Postdoctoral Fellow (now @ Cleveland Clinic)
2006 – 2009	Anna-Marie Bleau, PhD, Postdoctoral Fellow (now @ Pamplona, Spain)

2006 - 2010 Jason Huse, MD, PhD Neuropath Fellow (now @ MSK Assist Attend Path)
 2006 – 2012 Massimo Squarrito, PhD Postdoctoral Fellow (now @ CNIO)
 2006 – present Tatsuya Ozawa, MD PhD Postdoctoral Fellow
 2007 – 2009 Nduka Amankolor, MD, Neurosurgery resident (Yale University)
 2008 – 2011 Rebecca Bish, PhD, Postdoctoral Fellow (now @ NYU)
 2010 – 2011 Nikki Charles, PhD, Postdoctoral Fellow (now @ Fordham University)
 2010 – 2012 Elena Bazzoli, MD, Postdoctoral Fellow (now @ U. Turino)
 2011 - present Nanna Lindberg, PhD, Postdoctoral Fellow
 2011 – 2014 Alexander Pietras, PhD, Postdoctoral Fellow (now @ Lund University)
 2011 – 2013 Jillian Werbeck PhD, Postdoctoral Fellow (now @ J&J)
 2011 – 2013 Quincey LaPlant, MD, PhD, Postdoctoral Fellow (now @ MSKCC)
 2012 – 2013 Teodoro Pulvarenti, PhD, Postdoctoral Fellow (now @ J Ex Med)
 2012 - present Youngmi Kim, PhD, Postdoctoral Fellow
 2013 - present Siobhan Pattwell, Postdoctoral Fellow
 2013 - 2014 Daniel Silver, Postdoctoral Fellow (now @ Cleveland Clinic)

Clinical Fellows:

1998-present Supervised surgical training of neurosurgery fellows at MD Anderson, MSKCC and UW

Neurosurgery residents:

1998-2000 Participated in the neurosurgical training and supervision of Baylor and UTMB neurosurgery residents.
 2001– present Participated in neurosurgical training and supervision of Cornell neurosurgery residents.
 2013 – present Participated in neurosurgical training and supervision of University of Washington neurosurgery residents.

K08 mentees:

John Boockvar	K08 CA130985 9/15/08-8/31/13
Praveen Raju	K08 NS066083 8/1/09-6/30/14
Milan Chheda	K08 NS062907 9/1/09-11/30/14
Terreria Jones	K08 CA163765 9/1/13-8/31/18
Moritz Kirtcher	K08 CA163961 9/1/13-8/31-18
Sriram Venneti	K08 CA181475 1/1/13-12/31/18

INVITATIONS TO SPEAK AT NATIONAL OR INTERNATIONAL CONFERENCES (Since 1998):

1. Institute for Systems Biology, Seattle, WA, May 2014
2. AACR, San Diego CA, April 2014
3. Solerno, Italy, September 2013
4. Montreal, Canada, June 2013
5. Van Andle, Grand Rapids, May 2013
6. World Pharma Forum, Philadelphia, PA, June 2013
7. ANS, New Orleans LA, April 2013
8. AACR, Washington DC, April 2013
9. Society for Neurobiology, New Orleans, LA, November 2012
10. NSF, Arlington, VA, November 2012
11. Society for Neuroscience, New Orleans, October 2012
12. JAX Mouse Course, Bar Harbor, ME, August 2012
13. Cold Spring Harbor, Banbury, New York, July 2012
14. Fed. Euro. Neuro. Soc. Barcelona, Spain, June 2012

15. Seve Balesteros Glioblastoma Conference, Barcelona, Spain, June 2012
16. New York Academy of Sciences, New York, NY June 2012
17. MMHCC, Washington, DC, June 2012
18. European Glia meeting, Warsaw, Poland, May 2012
19. Growth factors and oncogenes (Westermarck retire), Uppsala University, May 2012
20. CERN investigators meeting, Houston, TX, April 2012
21. PSOC annual meeting, Tampa, FL, April 2012
22. Glioblastoma Conference, Paris, France, October 2011
23. Jackson Labs, Molecular Genetics of the mouse, Bar Harbor, ME, August 2011
24. Stem Cell Institute, Rome, Italy, June 2011
25. Seve Balesteros Glioblastoma Conference, Valencia, Spain, June 2011
26. Stem Cell Workshop, Essen, Germany, April 2011
27. AACR, Orlando, FL, March 2011 (2 talks)
28. Retroviral tumor modeling workshop, Stockholm, March 2011 (2 talks)
29. Pruess Conference, San Diego, CA, March 2011
30. MMHCC, Washington, DC, January 2011
31. DKFZ, Heidelberg Germany, December 2010
32. SNO, Toronto, Canada, November 2010 (2 talks)
33. PSOC MSKCC-Cornell, New York, NY, November 2010
34. Brain Tumor Biology, UCSF, San Francisco, CA, October 2010
35. Litwin Symposium on Alzheimer's, New York, NY, October 2010
36. Brain Tumors, Rome, Italy, October 2010
37. ESTRO, Barcelona, Spain, September, 2010
38. JAX Mouse Course, Bar Harbor, ME, August 2010
39. Brain Tumors and Differentiation, CSHL, July 2010
40. Beatson Conference, Glasgow, Scotland, July 2010
41. Society for Toxicological Pathology, Chicago IL, June, 2010
42. Neuro-oncology, Frankfurt, Germany, April 2010
43. European Neuropathology, St. Moritz, SZ, March 2010
44. AACR/Brain Tumors, San Diego, CA, December 2009
45. Forbeck Symposium, Hilton Head, SC, November 2009
46. Litwin Symposium, New York, NY, October 2009
47. Military Health Conference, Kansas City, MO, September 2009
48. Jackson Labs, Molecular Genetics of the Mouse, Bar Harbor, ME, August 2009
49. Brain Tumor Immunotherapy and Stem Cells, Aspen, CO, August, 2009
50. Hinterzartener Kreis, Cadenabbia, Italy, April 2009
51. Gordon Conference – Glia, Ventura, CA, March 2009
52. Society for Neuro-Oncology, Las Vegas, NV, November 2008
53. Molecular Oncology, Huntington Beach CA, October 2008
54. Johns Hopkins Brain Neuro-oncology Update, Baltimore, MD, September 2008
55. Jackson Labs, Molecular Genetics of the mouse, Bar Harbor ME, August 2008
56. Cold Spring Harbor Brain tumor Meeting, CSHL, NY, August 2008
57. Hedgehog Meeting, Stanford, CA, June 2008
58. AANS, Chicago, IL, April 2008 (Bittner Lecture)
59. AACR, San Diego, CA, April 2008
60. PTEN Meeting, Lansdown, VA, March 2008
61. NCI Metastasis Workshop, Bethesda, MD, January 2008
62. CUHK, Hong Kong, January 2008
63. SNO, Dallas, TX, November 2007
64. Preuss Foundation, La Jolla, CA, November 2007
65. Heidelberg, Germany, October 2007

66. JAX Mouse Course, Bar Harbor, ME, August 2007
67. European Society for Molecular Imaging, Naples, Italy, June 2007
68. NIH Stem Cell meeting, Bethesda, May 2007
69. Chicago Northwestern Brain Tumor Conference, Chicago, May 2007
70. AACR, Orlando, FL, April 2007
71. Spinal Cord Tumor Meeting, Bethesda, February 2007
72. TMEN NIH meeting Bethesda MD, January 2007
73. AACR, Los Angeles, CA, April 2007
74. Society for Neuro-Oncology, Orlando, FL, November 2006
75. Meeting on Cancer, DKFZ, Heidelberg, Germany, September 2006
76. Society for Molecular Imaging, Kona, Hawaii, August 2006
77. Jackson Labs Mouse Course, Bar Harbor, ME, August 2006
78. Brain tumor summit, Cleveland Clinic, May 2006
79. PTEN meeting, Madrid, Spain, May 2006
80. Stem Cell Meeting Lund University, Sweden, April 2006
81. PTEN meeting, Cold Spring Harbor, NY, March 2006
82. Brain Tumors and Stem Cells, MGH Boston MA, November 2005.
83. NF meeting, Banbury Center, Cold Spring Harbor, NY, November 2005.
84. EMBL Mouse Meeting, Heidelberg, Germany, October 2005
85. Neural Stem Cells and Brain Cancer, Rome, Italy, September 2005.
86. Jackson Labs Mouse Course, Bar Harbor, ME, August 2005
87. EMBL-Salk Oncogene meeting, La Jolla, CA, August 2005
88. Gordon Conference-Cancer, Bryant U. RI, July 2005
89. AACR workshop, Aspen, CO, July 2005
90. MMHCC CNS tumor meeting St. Louis, MO, June 2005
91. NSA, Orlando, FL, June 2005
92. ASNR, Toronto, Canada, May 2005
93. WFNO, Edinburgh, Scotland, May 2005
94. AACR, Anaheim, CA, April 2005 (4 talks)
95. OSU Brain Tumor Conference Columbus, OH, March 2005
96. ASPN, Pudenz Lecture, Maui, February 2005
97. Max Delbruck Center, Berlin, Germany, December 2004.
98. Society for Neuro-Oncology, Farber Lecture, Toronto, November 2004.
99. Congress of Neurological Surgeons, San Francisco, CA, October 2004
100. Society of Molecular Imaging, St. Louis, MO, September 2004
101. Jackson Laboratories, Molecular Genetics of the Mouse, Bar Harbor, ME, August 2004
102. Cold Spring Harbor Oncogene Meeting, August 2004
103. AACR Molecular Biology Course, Aspen, CO, July 2004
104. SPORE annual meeting Baltimore, MD, July 2004
105. MMHCC Meeting Washington, DC, July 2004
106. Annual Neuropathology Meeting, Cleveland, OH, 2004
107. Molecular Imaging Meeting, University of Michigan, Ann Arbor, June 2004
108. Juan March Meeting, Madrid, Spain, May 2004
109. Myelin Gordon Conference, Barga, Italy, May 2004
110. Second annual Brain Tumor Course, Houston, TX, May 2004
111. Joint Brain Tumors Funders meeting, Boston, MA, April 2004
112. EIO-IFOM Annual Meeting, Milan, Italy, March 2004
113. AACR mouse models meeting, Keystone, CO, February 2004
114. Prostate think tank meeting, Washington, DC, February 2004
115. NABIT national meeting, Atlanta, GA, November 2003
116. University of Vermont Cancer Center, Burlington, VT, October 2003

117. UCSD/Salk Institute, Mahajani Symposium, San Diego, CA, September. 2003
118. Jackson Laboratories, Molecular Genetics of the Mouse, Bar Harbor, ME, August 2003
119. Cleveland Clinic, Cleveland, OH, July 2003
120. SPORE/MMHCC meeting, Baltimore, MD, July 2003
121. AACR Molecular Biology Course, Aspen, CO, June 2003
122. ASCO, Chicago IL (2 talks), June 2003
123. International Brain Tumor Pathology Conference, Tokyo, Japan, May 2003
124. AACR Mouse Modeling Meeting, Orlando, FL, February 2003
125. Brain tumor course, MD Anderson, Conroe ,TX, February 2003
126. ABC2 biomarkers meeting San Francisco, CA, January 2003
127. Brain tumor SPORE meeting, San Francisco, CA, January 2003
128. ASTS annual meeting Miami, FL, January 2003
129. Seroussi Awards, Tel Aviv University, Tel Aviv, Israel, December 2002
130. Society for Neuro-Oncology-MMHCC, San Diego, CA, November 2002
131. Moderator/speaker, Modeling session of SNO, San Diego, CA, November 2002
132. Preclinical trials meeting of MMHCC, JAX labs, Bar Harbor, ME, October 2002
133. ABC2 annual meeting, Half Moon Bay, CA, July 2002
134. Mouse Model of Human Cancers Consortium MMHCC, Boston, MA, July 2002
135. AACR sunrise session, San Francisco, CA, April 2002
136. Neurofibromatosis Preclinical trials meeting, Washington DC, January 2002
137. NIH Working Group on Tumor Metastasis Washington DC, November 2001.
138. Society for Neuro-Oncology annual meeting. Washington, DC, November 2001
139. Symposium on Cancer Biology, Roswell Park, November 2001
140. Gordon Conference on Cancer Biology, Newport, RI, July 2001
141. Cleveland Clinic Special Symposium, Cleveland, OH, June 2001
142. National Neurofibromatosis Foundation annual meeting, Aspen, CO, May 2001
143. MD Anderson Special Symposium, Houston, TX, January 2001
144. Society for Neuro-Oncology meeting, Chicago, IL, November 2000
145. Organizer and Speaker, MMHCC preclinical trials meeting, Rockville, September 2000
146. Co-Chairman: Brain Tumor Progress Review Group (PRG), VA, July 2000
147. Mouse Model of Human Cancers Consortium MMHCC, Chantilly, VA, July 2000
148. Southwest Oncology Group Spring Meeting, Seattle, WA, April 2000
149. TVA Meeting, University of Pennsylvania, Philadelphia, PA, April 2000
150. International Life Sciences Institute (ILSI) St. Petersburg, FL, January 2000
151. Symposium in honor of Harold E. Varmus, Cold Springs Harbor, NY, December 1999
152. Moderator, Model Systems for Tumors. SNO, Scottsdale, AZ, November 1999
153. SNO, Scottsdale, AZ, November 1999.
154. TVA Annual Meeting NIH, Bethesda, MD January 1999
155. SNO, San Francisco, CA, November 1998
156. Society of Toxicologic Pathologists, Washington, DC, June 1999
157. Society for Neuro-oncology, SNO, Charlottesville, VA, October 1998
158. Howard Hughes Medical Institute, Chevy Chase, MD, September 1998
159. AACR, New Orleans, LA, April 1998

INSTITUTIONAL SEMINARS/VISITING PROFESSORSHIPS (Since 1998):

1. Stanford University, Palo Alto, CA, October 2014
2. Case Western Reserve, Cleveland, OH, March 2014
3. Uppsala University, Uppsala, Sweden, January 2014
4. FMI, Basel, Switzerland, May 2013
5. Van Andle, Grand Rapids, MI, May 2013

6. University of Washington, Seattle, WA, March 2013
7. Karolinska Institute, Stockholm, SW, March 2012
8. Uppsala University, SW, March 2013
9. MD Anderson, Houston, March 2013
10. New York Medical College, Valhalla, NY, February 2013
11. SUNY Downstate, Brooklyn, NY, February, 2013
12. Washington University, St Louis, MO, January 2013
13. Merck, Boston, October 2012
14. Cornell Medical School, New York, September 2012
15. Albert Einstein, Montefiore, New York, June 2012
16. University of Hamburg, Hamburg, Germany, February 2012
17. Tufts University, Boston, MA, January 2012
18. St Jude, Memphis, TN, October 2011
19. Cornell University Ithaca, NY, July 2011
20. Johns Hopkins, Baltimore, MD, May 2011
21. UMDNJ, Newark, NJ, May 2011
22. Cleveland Clinic, Cleveland, OH, April 2011
23. Ohio State University, Columbus, OH, April 2011
24. ImClone Pharmaceuticals, New York, NY, April 2011
25. Fred Hutchinson Cancer Center, Seattle, WA, March 2011
26. Uppsala University, Sweden, March 2011
27. U. Penn., Philadelphia, PA, June 2010
28. U. Tenn., Memphis TN, April 2010
29. Cold Spring Harbor, NY, January 2010
30. Mt Sinai, New York, NY. November 2009
31. NIH, Bethesda, MD, October 2009
32. Columbia University, New York, NY June 2009
33. Yale University, New Haven, CT, January 2009
34. Brigham and Women's, Boston, MA, December 2008
35. Stanford University, Palo Alto, CA December 2008
36. University of Calgary, Calgary, Alberta, November 2008
37. NYU, New York, NY, November 2008
38. U. Minn. Minneapolis, MN, October 2008
39. UCLA, Los Angeles, CA, April 2008
40. UCSF San Francisco, CA, March 2008
41. Boston Children's, Boston, MA, February 2008
42. University of Utah, Salt Lake City, December 2007
43. University of Michigan, October 2007
44. NIH Fredrick, MD, September 2007
45. Merck, Boston MA, February 2007
46. MD Anderson, Houston, TX, December 2006
47. New York University, New York, November 2006
48. Washington University, St. Louis, October 2006
49. University of Alabama, Birmingham AL, October 2006
50. Cornell University, New York, October 2006
51. Scripps Research Institute, La Jolla, CA, May 2006
52. University of Cincinnati, Cincinnati, OH, November 2005
53. NYU, New York, October 2005
54. Columbia University, New York, October 2005
55. Emory University, Atlanta, AL, May 2005
56. University of Florida, Gainesville, FL, March 2005 (2 talks)

57. Montefiore Medical Center, Bronx, NY, March 2005
58. Montreal Neurologic Institute, Killan Lecture, Montreal, March 2005
59. Genentech, South San Francisco, CA, January 2005
60. MGH East, Boston, January 2005
61. Case Western University, Cleveland, December 2004
62. Cornell University New York, September, 2004
63. Rockefeller University, New York, September 2004
64. University of Dusseldorf, Dusseldorf, Germany, September 2004
65. University of Toronto, Toronto, Canada, August 2004
66. New York University, New York City, June 2004
67. University of Basel/FMI/Novartis, Basel, Switzerland, April 2004
68. University of Paris, France, March 2004
69. University of Alabama Birmingham, AL, March 2004
70. Einstein Medical Center, Bronx, NY, March 2004
71. University of Toronto, LeBatt Lecture, Toronto, Canada, January 2004
72. Hospital for Sick Children, Labatt Annual Lecture, Toronto, January, 2004
73. Harvard Beth Israel, Boston, MA, November 2003
74. UCSF 7th Hoshino Lecture, San Francisco, CA September 2003
75. Genentech, South San Francisco, CA, September 2003
76. Univ. Calgary, Calgary, Canada, September 2003
77. Erasmus University, Rotterdam, Netherlands, June 2003
78. Karolinska Institute, Stockholm, Sweden, May 2003
79. Uppsala University, Uppsala, Sweden, May 2003
80. Cold Spring Harbor, January 2003
81. University of Virginia, January 2003
82. MD Anderson, Houston, TX December 2002
83. Novartis, Summit, NJ, December 2002
84. Surgery Grand Rounds, MSKCC, November 2002
85. Medicine Grand Rounds, MSKCC, October 2002
86. Columbia University, October 2002
87. Aton Pharmaceuticals, Tarrytown, NY, Sept. 2002
88. Millennium Pharmaceuticals, South San Francisco, CA, July 2002
89. Uppsala University, Sweden, June 2002
90. Harvard Medical School, May 2002
91. University of Michigan, May 2002
92. University of Illinois, March 2002
93. Washington University, February 2002
94. Duke University, January 2002
95. Rockefeller University, January 2002
96. Columbia University, January 2002
97. Cornell University, December 2001
98. Massachusetts General Hospital, December 2001
99. Novartis, December 2001
100. Columbia University, New York, NY, September 2001
101. Genentech, South San Francisco, CA, August 2001
102. Van Andle Research Institute, Grand Rapids MI, May 2000
103. UMDNJ-Robert Wood Johnson Medical School, May 2000
104. Thomas Jefferson University, Philadelphia, PA, May 2000
105. Baylor College of Medicine, Houston, TX, April 2000
106. Neurosurgery Grand Rounds, Mayo Clinic, February 2000
107. Tumor Biology Program, Mayo Graduate School, February 2000

108. St Jude Children's Research Hospital, Memphis, TN, December 1999
109. University of North Carolina, Chapel Hill, NC, November 1998
110. National Institutes of Health. Bethesda, MD, March 1998
111. Georgetown University, February 1998

Languages: English

Peer reviewed Publications:

1. Smith D, King J, **Holland EC**. (1982) Phosphonoacetic acid: Effects on and distribution in Tetrahymena. J. Protozool 29:103 – 105.
2. **Holland EC**, Leung J, Drickamer K. (1984) Rat liver asialoglycoprotein receptor lacks a cleavable NH₂-signal sequence. Proc Nat Acad Sci USA 81:7338 - 7342.
3. Leung J, **Holland EC**, Drickamer K. (1985) Characterization of the gene encoding the major rat liver asialoglycoprotein receptor. J Biol Chem 260:12523 - 12527.
4. Hsueh E, **Holland EC**, Carrera J, Drickamer K. (1986) The rat liver asialoglycoprotein receptor polypeptide must be inserted into a microsome to achieve active conformation. J Biol Chem 261:4940 - 4947.
5. **Holland EC**, Drickamer K. (1986) Signal recognition particle mediates the insertion of a transmembrane protein which has a cytoplasmic NH₂-terminus. J Biol Chem 261:1286 - 1292.
6. Halberg D, Wagner R, Farrell D, Hildreth J, Quesenberry M, Loeb J, **Holland EC**, Drickamer K. Major and minor forms of the rat liver asialoglycoprotein receptor are independent galactose-binding proteins. J Biol Chem 262:9828 - 9838, 1987.
7. Feng S, **Holland EC**. (1988) HIV-1 tat transactivation requires the loop sequence within tar. Nature 334:195 – 167.
8. **Holland EC**, Varmus H. (1988) Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci USA 95:1218 – 1223.
9. **Holland EC**, Hively W, Gallo V, Varmus H. (1988) Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of *CDK4* but not loss of *INK4a-ARF* induces hyperploidy in cultured mouse astrocytes. Genes Dev 12:3644-3649.
10. **Holland EC**, Hively W, DePinho R, Varmus H. (1998) A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12:3675-3685.
11. Fisher GH, Orsulic S, **Holland EC**, Hively WP, LI Y, Lewis BC, Williams BO, Varmus HE. (1999) Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 38: 5253-5260.
12. Dressman M, **Holland E**, Polymeropoulos MH, Lavedan CN. (1999) Signing on to expression profiles. Nature Genetics 23, 42-42 doi: 10.1038/14295.
13. **Holland, EC**. (2000) A mouse model for glioma: biology, pathology, and therapeutic opportunities. Toxicol Pathol 28:171-177.
14. **Holland EC**, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25:55-57.
15. **Holland, EC**. (2000) Glioblastoma Multiforme: the terminator. Proc Natl Acad Sci USA 97:6242-6244.
16. **Holland EC**, Li Yi, Celestino J, Dai C, Schaefer L, Sawaya R, Fuller GN. (2000) Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen *in vivo*. Am J Pathol 157:1031-7.

17. Caskey LS, Fuller GN, Bruner JM, Yung WK, Sawaya RE, **Holland EC**, Zhang W. (2000) Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling. Histol Histopathol 15:971-81.
18. Laywell ED, Rakic P, Kukekov VG, **Holland EC**, Steindler DA. (2000) Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proc Natl Acad Sci USA 97:13883-8.
19. **Holland EC** Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2(2):120-9, 2001.
20. **Holland EC**. (2001) Brain tumor animal models: importance and progress. Curr Opin Oncol 13:143-147.
21. **Holland EC**. (2001) Animal models of cell cycle dysregulation and the pathogenesis of gliomas. J Neurooncol 51:265-276, 2001.
22. Louis DN, **Holland, EC**, Cairncross JG. (2001) Glioma Classification: a molecular reappraisal. Am. J. Pathol 9:779-786.
23. Uhrbom L, **Holland EC**. (2001) Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors. J Neurooncol 53, 297-305.
24. Dai C, **Holland EC**. (2001) Glioma models. BBA Reviews Online 8;31:1551(1)M19-27.
25. Dai C, Celestino J, Okada Y, Louis DN, Fuller GN, **Holland EC**. (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913-1925.
26. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, **Holland EC**, Hess K, Michael C, Miller D, Sawaya R: (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurgery 95: 190-198.
27. **Holland EC**. (2001) Progenitor cells and glioma formation. Curr Opin Neurol Dec;14(6):683-8.
28. Lang FF, Olansen NE, DeMonte F, Gokaslan ZL, **Holland EC**, Kalthorn C, Sawaya R. (2001) Surgical resection of intrinsic insular tumors: complication avoidance. J Neurosurgery Oct;95(4):638-50.
29. Begemann M, Fuller GN, **Holland EC**. (2002) Genetic modeling of glioma formation in mice. Brain Pathol Jan;12(1):117-32.
30. Fults D, Pedone C, Dai C, **Holland EC**. (2002) MYC expression promotes the proliferation of Neural progenitors cells in culture and in vivo. Neoplasia 4: 32-39.
31. Van Rompaey L, **Holland EC**, Grosveld G. (2002) TEL Induces Aggregation in Transformed Cells and Induces Tube Formation in NIH3T3-UCLA Cells. Biochem Biophys Res Commun Mar 8;291(4):820-8.
32. De Miguel MP, Cheng L, **Holland EC**, Federspiel MJ, Donovan PJ. (2002) Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. Proc Natl Acad Sci USA Jul 24
33. Tanwar MK, Gilbert MR, **Holland EC**. (2002) Gene Expression Microarray Analysis Reveals YKL-40 to Be a Potential Serum Marker for Malignant Character in Human Glioma. Cancer Res Aug 1;62(15):4364-4368.
34. Koutcher JA, Hu X, Gede T, Leeds N, Zhao J, Zagzag D, **Holland EC**. (2002) MR imaging of mouse models for gliomas show similarities to humans and can be used to identify mice for preclinical trials. Neoplasia Nov;4(6):480-485.
35. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, **Holland EC**. (2002) *Ink4a-Arf* loss cooperates with *KRas* activation in astrocytes and neural progenitors to generate

- glioblastomas of various morphologies depending on amount of Akt activity. Cancer Res Oct 1;62(19):5551-5558.
36. Weiss WA, Israel M, Cobbs C, **Holland EC**, James CD, Louis DN, Marks C, McClatchey A, Roberts T, Van Dyke T, Wetmore C, Chiu I, Giovannini M, Guha A, Higgins R, Marino S, Radovanovic I, Reilly K, Aldape K. (2002) Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene Oct 24;21(49):7453-63.
 37. Xu S, Gade TP, Matei C, Zakian K, Alfieri AA, Hu X, **Holland EC**, Soghomonian S, Tjuvajev J, Ballon D, Koutcher JA. (2003) In vivo multiple-mouse imaging at 1.5 T. Magn Reson Med 551-557.
 38. Wolf RM, Draghi N, Liang X, Dai C, Uhrbom L, Eklof C, Westermarck B, **Holland EC**, Resh MD. (2003) p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human Chromosome 19q13.3. Genes Dev 476-87.
 39. Dai C, **Holland EC**. (2003) Astrocyte differentiation states and glioma formation. Cancer J Mar-Apr;9(2):72-81.
 40. Rao G, Pedone CA, Coffin CM, **Holland EC**, Fults DW. (2003) c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia May-Jun;5(3):198-204.
 41. Hesselager G, **Holland EC**. (2003) Using mice to decipher the molecular genetics of brain tumors. Neurosurgery Sep;53(3):685-95.
 42. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, **Holland EC**. (2003) Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell Oct;12(4):889-901.
 43. Collignon FP, **Holland EC**, Feng S. (2004) Organ Donors with Malignant Gliomas: An Update. Am J Transplant Jan;4(1):15-21.
 44. **Holland EC**. (2004) Regulation of Translation and Cancer. Cell Cycle. Apr
 45. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, **Holland EC**, Tempst PS. (2004) Serum Peptide profiling by magnetic particle-assisted, automated sample processing and maldi-tof mass spectrometry. Anal Chem Mar 15;76(6):1560-70.
 46. Rajasekhar VK, **Holland EC**. (2004) Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene Apr 19;23(18):3248-3264.
 47. **Holland EC**, Sonenberg N, Pandolfi PP, Thomas G. (2004) Signaling control of mRNA translation in cancer pathogenesis. Oncogene Apr 19;23(18):3138-44.
 48. Rao G, Pedone CA, Valle LD, Reiss K, **Holland EC**, Fults DW. (2004) Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23: 6156-6162.
 49. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, **Holland EC**. (2004) Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res. Jul 15;64(14):4783-9.
 50. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, Sabbatini P, Anderson S, Aghajanian C, **Holland EC**, Spriggs DR. (2004) Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. Aug 15;22(16):3330-9.
 51. **Holland EC**. (2004) Mouse models of human cancer as tools in drug development. Cancer Cell Sep;6(3):197-8.
 52. Uhrbom L, Nerio E, **Holland EC**. (2004) Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med Nov;10(11):1257-1260. Epub 2004 Oct 24.
 53. Lassman A, Dai C, Fuller GN, **Holland EC**. (2004) Overexpression of c-Myc promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt

- signaling to induce gliomas from GFAP-expressing cells in mice. Neuron Glia Biology 1, 157-163.
54. Parsa A, **Holland EC**. (2004) Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol Med Dec;10(12):607-13
 55. Shih A, **Holland EC**. (2004) Developmental neurobiology and the origin of brain tumors. J Neurooncology 70:125-136.
 56. Barbashina V, Salazar P, **Holland EC**, Rosenblum MK, Ladanyi M. (2005) Allelic Losses at 1p36 and 19q13 in Gliomas: Correlation with Histologic Classification, Definition of a 150-kb Minimal Deleted Region on 1p36, and Evaluation of CAMTA1 as a Candidate Tumor Suppressor Gene. Clin Cancer Res Feb 1;11(3):1119-28
 57. Uhrbom L, Kastemar M, Johansson FK, Westermark B, **Holland EC**. (2005) Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res Mar 15;65(6):2065-9
 58. Dai C, Lyustikman Y, Shih A, Hu X, Fuller GN, Rosenblum M, **Holland EC**. (2005) The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia Apr;7(4):397-406.
 59. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, **Holland EC**. mTOR Promotes Survival and Astrocytic Characteristics Induced by Pten/Akt Signaling in Glioblastoma. Neoplasia Apr;7(4):356-368.
 60. Fomchenko EI, **Holland EC**. (2005) Stem cells and brain cancer. Exp Cell Res Jun 10;306(2):323-9. Epub 2005 Apr 14.
 61. Hu X, **Holland EC**, (2005) Applications of mouse glioma models in preclinical trials, Mutat Res Aug 25;576(1-2):54-65
 62. Shih A, **Holland EC**. (2005) Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett Aug 30; [Epub ahead of print].
 63. Momota H, Nerio E, **Holland EC**. Perifosine Inhibits Multiple Signaling Pathways in Glial Progenitors and Cooperates with Temozolomide to Arrest Cell Proliferation in Gliomas *in vivo*. Cancer Res. 2005 Aug 15;65(16):7429-35
 64. Momota H, **Holland EC**. (2005) Bioluminescence technology for imaging cell proliferation. Curr Opin Biotechnol. 16, 681-686.
 65. Lassman AB, Rossi MR, Razier JR, Abrey LE, Lieberman FS, Greife CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, Deangelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, **Holland EC**. (2005) Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from north american brain tumor consortium trials 01-03 and 00-01. Clin Cancer Res Nov 1;11(21):7841-50.
 66. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, **Holland EC**, Cordon-Cardo C, Scher HI, Tempst P. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest Jan;116(1):271-84.
 67. Becher OJ, **Holland EC**, (2006) Genetically engineered models have advantages over Xenografts for preclinical studies. Cancer Res April 66:(7) 3355-3358.
 68. Salpietro M, **Holland EC**. (2005) Modeling and preclinical trials for gliomas. Clin Neurosurg 52:104-11.
 69. Fomchenko EI, **Holland EC**. (2006) Origins of brain tumors--a disease of stem cells? Nat Clin Pract Neurol Jun;2(6):288-9.
 70. Fomchenko EI, **Holland EC**. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res. 2006 Sep 15;12(18):5288-97.

71. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, Deangelis LM, **Holland EC**. YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas. Clin Cancer Res. 2006 Oct 1;12(19):5698-5704.
72. Hambardzumyan D, Squatrito M, **Holland EC**. Radiation resistance and stem-like cells in brain tumors. Cancer Cell. 2006 Dec;10(6):454-6.
73. Shih AH, **Holland EC**. Notch signaling enhances nestin expression in gliomas. Neoplasia. 2006 Dec;8(12):1072-82.
74. Fomchenko EI, **Holland EC**. Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. Neurosurg Clin N Am. 2007 Jan;18(1):39-58.
75. Tchougounova E, Kastemar M, Brasater D, **Holland EC**, Westermarck B, Uhrbom L. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene. 2007 Sep 20;26(43):6289-96.
76. Bradley SV, **Holland EC**, Liu GY, Thomas D, Hyun TS, Ross TS. Huntingtin Interacting Protein 1 Is a Novel Brain Tumor Marker that Associates with Epidermal Growth Factor Receptor. Cancer Res. 2007 Apr 15;67(8):3609-15.
77. Bleau AM, **Holland EC**. Trapping the mouse genome to hunt human alterations. Proc Natl Acad Sci U S A. 2007 May 8;104(19):7737-8. Epub 2007 May 3.
78. McConville P, Hambardzumyan D, Moody JB, Leopold WR, Kreger AR, Woolliscroft MJ, Rehemtulla A, Ross BD, **Holland EC**. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res. 2007 May 15;13(10):2897-904.
79. Dunlap SM, Celestino J, Wang H, Jiang R, **Holland EC**, Fuller GN, Zhang W. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11736-41. Epub 2007 Jul 2.
80. Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, **Holland EC**, Ross BD, Rehemtulla A. Molecular imaging of Akt kinase activity. Nat Med. 2007 Sep;13(9):1114-9
81. Lassman AB, **Holland EC**. Incorporating molecular tools into clinical trials and treatment for gliomas? Curr Opin Neurol. 2007 Dec;20(6):708-11
82. Liu Y, Yeh N, Zhu XH, Leversha M, Cordon-Cardo C, Ghossein R, Singh B, **Holland EC**, Koff A. Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1). EMBO J. 2007 Nov 14;26(22):4683-93. Epub 2007 Oct 18
83. Hambardzumyan D, Lyustikman Y, **Holland EC**. An update on mouse brain tumor models in cancer drug discovery. Expert Opinion on Drug Discovery. 2, (11), Nov 2007, 1435-1451.
84. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, **Holland EC**. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008 Feb 15;22(4):436-48.
85. Bradbury MS, Hambardzumyan D, Zanzonico PB, Schwartz J, Cai S, Burnazi EM, Longo V, Larson SM, **Holland EC**. Dynamic Small-Animal PET Imaging of Tumor Proliferation with 3'-Deoxy-3'-18F-Fluorothymidine in a Genetically Engineered Mouse Model of High-Grade Gliomas. J Nucl Med. 2008 Feb 20;
86. Bleau AM, Howard BM, Taylor LA, Gursel D, Greenfield JP, Lim Tung HY, **Holland EC**, Boockvar JA. New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans. Neurosurg Focus. 2008;24(3-4):E28

87. Momota H, Shih AH, Edgar MA, **Holland EC**. c-Myc and beta-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice. Oncogene. 2008 Mar 31.
88. Becher OJ, Hambardzumyan D, Fomchenko EI, Momota H, Mainwaring L, Bleau AM, Katz AM, Edgar M, Kenney AM, Cordon-Cardo C, Blasberg RG, **Holland EC**. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res. 2008 Apr 1;68(7):2241-9.
89. Hambardzumyan D, Becher OJ, **Holland EC**. Cancer stem cells and survival pathways. Cell Cycle. 2008 Mar 19;7(10)
90. Lyustikman Y, Momota H, Pao W, **Holland EC**. Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia. 2008 May;10(5):501-10.
91. Dudu V, Ramcharan M, Gilchrist ML, **Holland EC**, Vazquez M. Liposome delivery of quantum dots to the cytosol of live cells. J Nanosci Nanotechnol. 2008 May;8(5):2293-300.
92. Hambardzumyan D, Squatrito M, Carbajal E, **Holland EC**. Glioma Formation, Cancer Stem Cells, and Akt Signaling. Stem Cell Rev. 2008 Jul 2.
93. Brenet F, Socci ND, Sonenberg N, **Holland EC**. Akt phosphorylation of La regulates specific mRNA translation in glial progenitors. Oncogene. 2008 Oct 6.
94. Perry A, Miller CR, Gujrati M, Scheithauer BW, Zambrano SC, Jost SC, Raghavan R, Qian J, Cochran EJ, Huse JT, **Holland EC**, Burger PC, Rosenblum MK. Malignant Gliomas with Primitive Neuroectodermal Tumor-like Components: A Clinicopathologic and Genetic Study of 53 Cases. Brain Pathol. 2009 Jan;19(1):81-90.
95. Huse JT, **Holland EC**. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol. 2009 Jan;19(1):132-43.
96. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, **Holland EC**. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009 Mar 6;4(3):226-35.
97. Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, **Holland EC**. Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol. 2009 May;2(2):89-95.
98. Sabharwal N, **Holland EC**, Vazquez M. Live Cell Labeling of Glial Progenitor Cells Using Targeted Quantum Dots Ann Biomed Eng. 2009 May 5.
99. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, **Holland EC**. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 2009 Jun 1;23(11):1327-37.
100. Amankulor NM, Hambardzumyan D, Pyonteck SM, Becher OJ, Joyce JA, **Holland EC**. Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. J Neurosci. 2009 Aug 19;29(33):10299-308.
101. Bleau AM, Huse JT, **Holland EC**. The ABCG2 resistance network of glioblastoma. Cell Cycle. 2009 Sep 13;8(18).
102. Bhatia B, Northcott PA, Hambardzumyan D, Govindarajan B, Brat DJ, Arbiser JL, **Holland EC**, Taylor MD, Kenney AM. Tuberos Sclerosis Complex Suppression in Cerebellar Development and Medulloblastoma: Separate Regulation of Mammalian Target of Rapamycin Activity and p27Kip1 Localization. Cancer Res. 2009 Sep 8
103. Charles N, **Holland EC**. Brain tumor treatment increases the number of cancer stem-like cells. Expert Rev Neurother. 2009 Oct;9(10):1447-9
104. Bleau AM, **Holland EC**. [Chemotherapeutic treatment of gliomas increases the amount of cancer stem-like cells.] Med Sci (Paris). 2009 Oct;25(10):775-777

105. Huse JT, **Holland EC**. Yin and yang: Cancer-implicated miRNAs that have it both ways. Cell Cycle. 2009 Nov 24;8(22).
106. Ayuso-Sacido A, Moliterno JA, Kratovac S, Kapoor GS, O'Rourke DM, **Holland EC**, García-Verdugo JM, Roy NS, Boockvar JA. Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. J Neurooncol. 2009 Oct 24.
107. Momota H, **Holland EC**. Mouse models of CNS embryonal tumors. Brain Tumor Pathol. 2009;26(2):43-50.
108. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, **Holland E**. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009 Nov 13;4(11):e7752
109. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, **Holland EC**, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2010 42 (1) 77-82.
110. See WL, Miller JP, Squatrito M, **Holland EC**, Resh MD, Koff A. Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas. Oncogene. 2010 Jan 11.
111. Charles NA, **Holland EC**. TRRAP and the Maintenance of Stemness in Gliomas.. Cell Stem Cell. 2010 Jan 8;6(1):6-7.
112. Claus EB, Abdel-Wahab M, Burger PC, Engelhard HH, Ellison DW, Gaiano N, Gutmann DH, Heck DA, **Holland EC**, Jallo GI, Kruchko C, Kun LE, Maria BL, Rumboldt Z, Seminara D, Spinella GM, Stophel L, Wechsler-Reya R, Wrensch M, Gilbertson RJ.. Defining future directions in spinal cord tumor research. J Neurosurg Spine. 2010 Feb;12(2):117-21.
113. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D, **Holland EC**. Perivascular Nitric Oxide Activates Notch Signaling and Promotes Stem-like Character in PDGF-Induced Glioma Cells.. Cell Stem Cell. 2010 Feb 5;6(2):141-152.
114. Becher OJ, Hambardzumyan D, Walker TR, Helmy K, Nazarian J, Albrecht S, Hiner RL, Gall S, Huse JT, Jabado N, Macdonald TJ, **Holland EC**. Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma. Cancer Res. 2010 Mar 2.
115. See WL, Heinberg AR, **Holland EC**, Resh MD. p27 deficiency is associated with migration defects in PDGF-expressing gliomas in vivo. Cell Cycle. 2010 Apr 19;9(8).
116. Huse JT, **Holland EC**. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010 May;10(5):319-31.
117. Charles N, **Holland EC**. The perivascular niche microenvironment in brain tumor progression. Cell Cycle. 2010 Aug 17;9(15).
118. Howard BM, Gursel DB, Bleau AM, Beyene RT, **Holland EC**, Boockvar JA.. EGFR signaling is differentially activated in patient-derived glioblastoma stem cells. J Exp Ther Oncol. 2010;8(3):247-60.
119. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, Huse JT, Pedraza A, Utsuki S, Yasui Y, Tandon A, Fomchenko EI, Oka H, Levine RL, Fujii K, Ladanyi M, **Holland EC**. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev. 2010 Oct 1;24(19):2205-18

120. Becher OJ, **Holland EC**. Evidence for and against regional differences in neural stem and progenitor cells of the CNS. Genes Dev. 2010 Oct 15;24(20):2233-8
121. Jones TS, **Holland EC**. Molecular Pathogenesis of Malignant Glial Tumors. Toxicol Pathol. 2010 Nov 15.
122. Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, **Holland EC**. Loss of ATM/Chk2/p53 Pathway Components Accelerates Tumor Development and Contributes to Radiation Resistance in Gliomas. Cancer Cell. 2010 Dec 14;18(6):619-29.
123. Leder K, **Holland EC**, Michor F. The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS One. 2010 Dec 17;5(12):e14366.
124. Ramirez CN, Ozawa T, Takagi T, Antczak C, Shum D, Graves R, **Holland EC**, Djaballah H. Validation of a High-Content Screening Assay Using Whole-Well Imaging of Transformed Phenotypes. Assay Drug Dev Technol. 2010 Dec 23.
125. Pitter KL, Galbán CJ, Galbán S, Saeed-Tehrani O, Li F, Charles N, Bradbury MS, Becher OJ, Chenevert TL, Rehemtulla A, Ross BD, **Holland EC**, Hambardzumyan D. Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma. PLoS One. 2011 Jan 18;6(1):e14545.
126. Hambardzumyan D, Parada LF, **Holland EC**, Charest A. Genetic modeling of gliomas in mice: New tools to tackle old problems. Glia. 2011 Feb 8. doi: 10.1002/glia.21142.
127. Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M, **Holland EC**, Deangelis LM, Hormigo A. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol. 2011 Jan 10. doi: 10.1002/ana.22360
128. Gronych J, Korshunov A, Bageritz J, Milde T, Jugold M, Hambardzumyan D, Remke M, Hartmann C, Witt H, Jones DT, Witt O, Heiland S, Bendszus M, **Holland EC**, Pfister S, Lichter. An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest. 2011 Mar 14. pii: 44656. doi: 10.1172/JCI44656
129. Charles NA, **Holland EC**, Gilbertson R, Glass R, Kettenmann H. (2011) The brain tumor microenvironment. Glia 59(8):1169-80.
130. Wee B, Charles N, **Holland EC**. (2011) Animal models to study cancer-initiating cells from Glioblastoma. Front Biosci (Landmark Ed) 16:2243-58.
131. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, **Holland EC**, Hormigo A. Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J Neurooncol. 2011 Jun 28.
132. Fomchenko EI, Dougherty JD, Helmy KY, Katz AM, Pietras A, Brennan C, Huse JT, Milosevic A, **Holland EC**. Recruited Cells Can Become Transformed and Overtake PDGF-Induced Murine Gliomas In Vivo during Tumor Progression. PLoS One. 2011;6(7):e20605. Epub 2011 Jul 6.
133. Halliday JJ, **Holland EC**. Connective Tissue Growth Factor and the Parallels Between Brain Injury and Brain Tumors. Natl Cancer Inst. 2011 Jul 19.
134. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, **Holland EC**, Hormigo A. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol. 2011 Aug 10.
135. Ciznadija D, Liu Y, Pyonteck SM, **Holland EC**, Koff A. CyclinD1 and cdk4 mediate development of neurologically destructive oligodendroglioma. Cancer Res. 2011 Oct 1;71(19):6174-83. Epub 2011 Aug 15

136. Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, **Holland EC**, Blasberg RG. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. *FASEB J*. 2011 Aug 19.
137. Fernandez-L A, Squatrito M, Northcott P, Awan A, **Holland EC**, Taylor MD, Nahlé Z, Kenney AM. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. *Oncogene*. 2011 Aug 29. doi: 10.1038/onc.2011.379.
138. Jones TS, **Holland EC**. Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. *Oncogene*. 2011 Sep 12. doi: 10.1038/onc.2011.398.
139. Lefave CV, Squatrito M, Vorlova S, Rocco GL, Brennan CW, **Holland EC**, Pan YX, Cartegni L. Splicing factor hnRNP H drives an oncogenic splicing switch in gliomas. *EMBO J*. 2011 Sep 13;30(19):4084-9.
140. Squatrito M, **Holland EC**. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. *Cancer Res*. 2011 Sep 15;71(18):5945-9.
141. Hambardzumyan D, Cheng YK, Haeno H, **Holland EC**, Michor F. The Probable Cell of Origin of NF1- and PDGF-Driven Glioblastomas. *PLoS One*. 2011;6(9):e24454. Epub 2011 Sep 9.
142. Jones TS, **Holland EC**. Animal models for glioma drug discovery. *Expert Opin Drug Discov*. 2011 Dec;6(12):1271-83. Epub 2011 Oct 28.
143. Cheng YK, Beroukhi R, Levine RL, Mellinghoff IK, **Holland EC**, Michor F. A Mathematical Methodology for Determining the Temporal Order of Pathway Alterations Arising during Gliomagenesis. *PLoS Comput Biol*. 2012 Jan;8(1):e1002337. Epub 2012 Jan 5.
144. Hofstetter CP, Burkhardt JK, Shin BJ, Gürsel DB, Mubita L, Gorrepati R, Brennan C, **Holland EC**, Boockvar JA. Protein Phosphatase 2A Mediates Dormancy of Glioblastoma Multiforme-Derived Tumor Stem-Like Cells during Hypoxia. *PLoS One*. 2012;7(1):e30059. Epub 2012 Jan 11.
145. Barrett LE, Granot Z, Coker C, Iavarone A, Hambardzumyan D, **Holland EC**, Nam HS, Benzra R. Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. *Cancer Cell*. 2012 Jan 17;21(1):11-24.
146. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, **Holland EC**, Huse JT, Jhanwar S, Leversha MA, Mikkelsen T, Brennan CW. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. *Proc Natl Acad Sci U S A*. 2012 Feb 8.
147. Lindberg N, **Holland EC**. PDGF in gliomas: more than just a growth factor? (2012) *Ups J Med Sci* 117(2): 92-8.
148. Charles NA, **Holland EC**, Gilbertson R, Glass R, Kettenmann H. (2012) The brain tumor microenvironment. *Glia* 60(3):502-14.
149. Katz AM, Amankulor NM, Pitter K, Helmy K, Squatrito M, **Holland EC**. Astrocyte-Specific Expression Patterns Associated with the PDGF-Induced Glioma Microenvironment. *PLoS One*. 2012;7(2):e32453. Epub 2012 Feb 29.
150. Silber J, Jacobsen A, Ozawa T, Harinath G, Pedraza A, Sander C, **Holland EC**, Huse JT. miR-34a Repression in Proneural Malignant Gliomas Upregulates Expression of Its Target PDGFRA and Promotes Tumorigenesis. *PLoS One*. 2012;7(3):e33844. Epub 2012 Mar 27.
151. Kircher MF, de la Zerda A, Jokerst JV, Zavaleta CL, Kempen PJ, Mittra E, Pitter K, Huang R, Campos C, Habte F, Sinclair R, Brennan CW, Mellinghoff IK, **Holland EC**,

- Gambhir SS. A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. *Nat Med*. 2012 Apr 15.
152. Galbán S, Lemasson B, Williams TM, Li F, Heist KA, Johnson TD, Leopold JS, Chenevert TL, Lawrence TS, Rehemtulla A, Mikkelsen T, **Holland EC**, Galbán CJ, Ross BD. DW-MRI as a Biomarker to Compare Therapeutic Outcomes in Radiotherapy Regimens Incorporating Temozolomide or Gemcitabine in Glioblastoma. *PLoS One*. 2012;7(4):e35857. Epub 2012 Apr 20
 153. Dougherty JD, Fomchenko EI, Akuffo AA, Schmidt E, Helmy KY, Bazzoli E, Brennan CW, **Holland EC**, Milosevic A. Candidate pathways for promoting differentiation or quiescence in oligodendrocyte progenitor-like cells in glioma. *Cancer Res*. 2012 Aug 3.
 154. Squatrito M, Vanoli F, Schultz N, Jasin M, **Holland EC**. 53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma. *Cancer Res*. 2012 Aug 21.
 155. Komotar RJ, Iorgulescu JB, Raper DM, **Holland EC**, Beal K, Bilsky MH, Brennan CW, Tabar V, Sherman JH, Yamada Y, Gutin PH. The role of radiotherapy following gross-total resection of atypical meningiomas. *J Neurosurg*. 2012 Aug 24.
 156. Setty M, Helmy K, Khan AA, Silber J, Arvey A, Neezen F, Agius P, Huse JT, **Holland EC**, Leslie CS. Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. *Mol Syst Biol*. 2012 Aug 28;8:605. doi: 10.1038/msb.2012.37.
 157. Helmy K, Halliday J, Fomchenko E, Setty M, Pitter K, Hafemeister C, **Holland EC**. Identification of Global Alteration of Translational Regulation in Glioma In Vivo. *PLoS One*. 2012;7(10):e46965. Epub 2012 Oct 3.
 158. Huse JT, **Holland EC**, Deangelis LM. Glioblastoma: Molecular Analysis and Clinical Implications. *Annu Rev Med*. 2012 Oct 3
 159. Bazzoli E, Pulvirenti T, Oberstadt MC, Perna F, Wee B, Schultz N, Huse JT, Fomchenko EI, Voza F, Tabar V, Brennan CW, Deangelis LM, Nimer SD, **Holland EC**, Squatrito M. MEF Promotes Stemness in the Pathogenesis of Gliomas. *Cell Stem Cell*. 2012 Dec 7;11(6):836-844.
 160. Benezra M, Hambardzumyan D, Penate-Medina O, Veach DR, Pillarsetty N, Smith-Jones P, Phillips E, Ozawa T, Zanzonico PB, Longo V, **Holland EC**, Larson SM, Bradbury MS. Fluorine-labeled Dasatinib Nanoformulations as Targeted Molecular Imaging Probes in a PDGFB-driven Murine Glioblastoma Model. *Neoplasia*. 2012 Dec;14(12):1132-43.
 161. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert R, Omay SB, Mishra-Gorur K, Choi M, Overton JD, **Holland EC**, Mane S, State MW, Bilgiivar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kiliç T, Lifton RP, Noonan JP, Yasuno K, Günel M. Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO. *Science*. 2013 Jan 24.
 162. Physical Sciences - Oncology Centers Network, Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, **Holland EC**, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V,

- O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH. A physical sciences network characterization of non-tumorigenic and metastatic cells. *Sci Rep*. 2013 Apr 25;3:1449.
163. Williams TM, Galbán S, Li F, Heist KA, Galbán CJ, Lawrence TS, **Holland EC**, Thomae TL, Chenevert TL, Rehemtulla A, Ross BD. DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases. *Transl Oncol*. 2013 Apr;6(2):133-42.
164. Antczak C, Wee B, Radu C, Bhinder B, **Holland EC**, Djaballah H. A High-Content Assay Strategy for the Identification and Profiling of ABCG2 Modulators in Live Cells. *Assay Drug Dev Technol*. 2013 Aug 30.
165. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW, Sutton JC, **Holland EC**, Daniel D, Joyce JA. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. *Nat Med*. 2013 Oct;19(10):1264-1272.
166. Liu Y, Raheja R, Yeh N, Ciznadija D, Pedraza AM, Ozawa T, Hukkelhoven E, Erdjument-Bromage H, Tempst P, Gauthier NP, Brennan C, **Holland EC**, Koff A. TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1). *Oncogene*. 2014 Jan 14;33(3): 308-15.
167. Leder K, Pitter K, Laplant Q, Hambarzumyan D, Ross BD, Chan TA, **Holland EC**, Michor F. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. *Cell*. 2014 Jan 30;156(3):603-16. doi: 10.1016/j.cell.2013.12.029.
168. Pietras A, Katz AM, Ekström EJ, Wee B, Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT, **Holland EC**. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. *Cell Stem Cell*. 2014 Mar 6;14(3):357-69.
169. Halliday J, Helmy K, Pattwell SS, Pitter KL, LaPlant Q, Ozawa T, **Holland EC**. In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. *Proc Natl Acad Sci U S A*. 2014 Apr 8;111(14):5248-53. doi: 10.1073/pnas.1321014111. Epub 2014 Mar 24.
170. Ortiz B, Fabius AW, Wu WH, Pedraza A, Brennan CW, Schultz N, Pitter KL, Bromberg JF, Huse JT, **Holland EC**, Chan TA. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. *Proc Natl Acad Sci USA*. 2014 May 19. pii: 201401952.
171. Park JH, Lee H, Makaryus R, Yu M, Smith SD, Sayed K, Feng T, **Holland E**, Van der Linden A, Bolwig TG, Enkolopov G, Benveniste H. Metabolic profiling of dividing cells in live rodent brain by proton magnetic resonance spectroscopy (1HMRS) and LCModel analysis. *PLoS One*. 2014 May 12;9(5):e94755.
172. Pitter KL, Tamagno I, Feng X, Ghosal K, Amankulor N, **Holland EC**, Hambarzumyan D. The SHH/Gli pathway is reactivated in reactive glia and drives proliferation in response to neurodegeneration-induced lesions. *Glia*. 2014 Jun 4; 62(10): 1595-607.
173. Becher OJ, **Holland EC**. Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma. *EMBO J*. 2014 Jul 24; 33(18): 1984-6.

174. Ozawa T, Riester M, Cheng YK, Huse JT, Squatrito M, Helmy K, Charles N, Michor F, **Holland EC**. Most Human Non-GCIMP Glioblastoma Subtypes Evolve from a Common Proneural-like Precursor Glioma. Cancer Cell. 2014 Aug 11;26(2):288-300.
175. Karabeber H, Huang R, Iacono P, Samii JM, Pitter K, **Holland EC**, Kircher MF. Guiding Brain Tumor Resection Using Surface-Enhanced Raman Scattering Nanoparticles and a Hand-Held Raman Scanner. ACS Nano. 2014 Aug 22; 8(10):9755-66.
176. Lindberg N, Jiang Y, Xie Y, Bolouri H, Kastemar M, Olofsson T, **Holland EC**, Uhrbom L. Oncogenic signaling is dominant to cell of origin and dictates astrocytic or oligodendroglial tumor development from oligodendrocyte precursor cells. J Neurosci. 2014 Oct 29; 34(44):14644-51.

Books/special issues edited:

1. **Holland EC**. Mechanisms for insertion of transmembrane proteins. PhD Thesis, University of Chicago 1986
2. **Holland EC** Ed. Mouse Models of Human Cancer. (2004) Wiley-Liss. Hoboken New Jersey.
3. **Holland EC**, Sontheimer H, Hambardzumyan D. Eds. Glia - Special Issue: Glioma, Volume 59, Issue 8 (Aug 2011).

Patents:

1. Transgenic animal and uses thereof, **EC Holland**, US Patent App. 20,040/139,487 - 2003. EP Patent 1,546,705 - 2005
2. Transgenic luciferase mouse **EC Holland**, US Patent 7,041,869 – 2006